2 Feb 2010 07:00
| For immediate release | 2nd February 2010 |
Futura Medical plc
("Futura" or "the Company")
CSD500 Update
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces an update on progress towards the marketing authorisation of its lead product, CSD500, which is scheduled to be launched as a Durex®-branded condom by SSL International plc (SSL).
Data is still being collected however the initial validation of the changes made to improve the manufacturing process has now been completed and accordingly Futura and SSL are currently updating the regulatory dossier necessary for CE Mark approval. Futura anticipates that SSL will submit the dossier to the relevant Notified Body in March 2010.
For any further information please contact:
| Futura Medical plc |
|
| James Barder, Chief Executive | Tel: +44 (0) 1483 685 670 |
|
|
|
| mail to: james.barder@futuramedical.com | www.futuramedical.com |
|
|
|
| Nomura Code Securities Limited |
|
| Phil Walker / Giles Balleny | Tel:+44 (0)20 7776 1200 |
|
|
|
| For media enquiries please contact: |
|
|
|
|
| Buchanan Communications |
|
| Mark Court / Stasa Filiplic / Jennie Spivey | Tel: +44 (0) 20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
Futura Medical (FUM)